Aardvark doses first patient in Australia Phase 3 HERO trial; Q3 2026 data readout on track

Aardvark Therapeutics, Inc.

First patient dosed in Australia in Phase 3 HERO trial for ARD-101 for hyperphagia in Prader-Willi syndrome.
Regulatory clearance received for clinical trial sites in Canada and UK; EU sites not needed for full enrollment.
All patients completing the 12-week HERO trial have enrolled in the Open Label Extension, indicating strong patient interest.
Topline data readout remains on track for Q3 2026 driven by strong US enrollment and international progress.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.